A pilot randomized trial of older adults with mild cognitive impairment given either daily low-dose lithium carbonate or placebo for 2 years met its feasibility target, according to results published ...
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial ...
Additional data presented further reinforces the favorable and consistent safety and efficiency profile of the VARIPULSE platform ii,iii,iv,v Additional VARIPULSE Platform data presented at AF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results